CER Daily Newsfeed

Hubs East 2025: The Patient Access Landscape

(3/24, Nicholas Saraceno, Pharmaceutical Commerce) comments “...An interesting study that [NPC’s Kimberly Westrich presented] revolved around patient experiences with their employer, AFP vendor, and application processes—not only was the average reported wait time to receive medication two months, but 24% of patients reported that delays in receiving their medication caused their condition to worsen, while 64% of patients said the wait to receive meds led to stress and/or anxiety.” Full

Adalimumab Biosimilars Comparable to Originator for Treatment of Psoriasis

(3/25, Tim Smith, HCPLive) reports “Adalimumab biosimilars Amjevita and Imraldi show comparable efficacy to Humira in psoriasis treatment, based on real-world data from BADBIR. The study involved over 11,400 participants, with analyses for new users and switchers, showing no significant differences in PASI scores between biosimilars and Humira.” Full

Shared Savings Program ACOs Wary as CMS Halts Pay Models

(3/25, Bridget Early, Modern Healthcare) reports “...CMS has ways to achieve higher savings without disrupting what makes the Medicare Shared Savings Program attractive to providers, said Aisha Pittman, senior vice president of government affairs for the National Association of ACOs. For instance, the agency could improve interoperability quality reporting, tweak the financial benchmarks formula and alleviate administrative burden, she said. Yet Medicare Shared Savings Program participants and their representatives are anxious that it may be at risk, or at least may be transformed into something significantly narrower.” Subscription Required